Sensei Biotherapeutics, INC 8-K filings

Sensei Biotherapeutics' lead drug candidate, SNS-101, shows encouraging initial clinical activity and a favorable safety profile in early-stage trials, targeting the VISTA immune checkpoint.

Sensei Biotherapeutics reported encouraging initial clinical data from its Phase 1/2 trial of SNS-101, showing potential in treating advanced solid tumors.

Sensei Biotherapeutics announced first quarter 2024 financial results, highlighted by the completion of SNS-101 dose escalation with no dose-limiting toxicities and a cash runway into the fourth quarter of 2025.

Sensei Biotherapeutics has entered into a consulting agreement with its former Chief Financial Officer, Erin Colgan, for transition services through April 30, 2024.

Sensei Biotherapeutics' Chief Financial Officer, Erin Colgan, has voluntarily resigned, effective April 10, 2024.

Sensei Biotherapeutics has extended the expiration date of its stockholder rights agreement to March 7, 2025, and removed certain obsolete language.

Sensei Biotherapeutics reported its full year 2023 financial results and provided an update on its lead candidate SNS-101, including an accelerated timeline for topline data.

Sensei Biotherapeutics reports the resignation of a board member and subsequent changes to board composition and committee leadership.